Bryant C. Nelson ()

Research Interests

Extracellular vesicles for drug delivery and gene therapy applications

Extracellular vesicles (EVs) are non-replicating lipid bilayer vesicles that are shed by almost all types of eukaryotic and prokaryotic cells under both physiological and pathological conditions.  Extending in size over the nanometer to micrometer size range (Figure 1), EVs are biological vectors intimately involved in cell-to-cell communication via the lateral transfer of coding and non-coding RNAs, small amounts of DNA, surface and cytoplasmic proteins, phospholipids and soluble small molecules to recipient cells.  They have been shown, in many fundamental and preclinical studies, to possess low immunogenicity, minimal complement activation potential, low toxicity and excellent biocompatibility.  In the context of EV technology development for the delivery of nucleic acid- or protein-based therapeutics, there exists a critical need to develop robust and reproducible methods for isolating, purifying and processing EV samples from a variety of sources for downstream analytical characterization. Please visit: https://pubmed.ncbi.nlm.nih.gov/32885720/.  Our team focuses on developing and standardizing analytical methods and developing reference materials (RMs) for characterizing the physicochemical and biological quality attributes of non-viral, nano-enabled drug delivery vectors such as EVs and lipid nanoparticles (LNPs).  Current laboratory efforts are directed towards evaluating the quality and effectiveness of traditional (e.g., TFF) and emerging (e.g., chromatography based) methodologies for isolating and purifying cell- and blood derived EVs.

Current Research Areas of Significance:

1. Development of standardized methods and measurements for isolating, purifying and processing EVs to enable their downstream utility in next-generation regenerative medicines and advanced therapies (RMATs) and as general drug delivery vectors.
2. Development of standardized methods and measurements that allow the scalable use of EVs as clinical biomarkers in plasma and/or as in vitro biomarkers of cell induced toxicity (liquid biopsies).   Both processes measure expression levels of key biological molecules.  A key challenge is the low level of biomarkers (e.g., cancer biomarkers: proteins, miRNAs) and the elevated levels of biological contaminants (e.g., lipoproteins, platelet-derived EVs) in plasma samples that may preclude early detection of the targeted biomarker.
3. Development of standardized methods and measurements that will allow the production of EV-based biological reference materials.
   • For additional information on all of these ongoing research areas, please see: Gene Delivery Systems

Lipid nanoparticle (LNP) documentary standards and analytical test methods

LNPs have emerged as an important nanoscale drug delivery technology for the in vivo intracellular delivery of therapeutic proteins and nucleic acids.  The safe and efficient delivery of therapeutic proteins and nucleic acids to cells and tissues can enable the effective treatment and prevention of a wide range of human diseases (e.g., cancers, infectious diseases, etc.) and facilitate innovations in regenerative medicine and other advanced therapies. Documentary standards and robust analytical methodology for establishing high quality characterization of ribonucleic acids - RNAs (specifically mRNA) encapsulated in LNPs are critically needed by mRNA-LNP product manufacturers and regulatory authorities.  Our lab is co-leading along with ASTM International, the FDA and key industry and academic partners, the development of both documentary standards and analytical test methods that will enable the characterization of mRNA encapsulation efficiency (e.g., the amount of free versus total mRNA encapsulated in LNP vectors), the qualitative or quantitative extraction of LNP encapsulated mRNA and the characterization of identity, integrity and purity of mRNA before and after encapsulation in LNP vectors.  It is expected that at the conclusion of this multiyear project, a comprehensive and impactful standard guide that describes the key technical considerations and recommended best practices, including suitable analytical methods and tools, will be available to industry, academia and regulatory stakeholders worldwide.  The standard will enable stakeholders to make informed decisions regarding the best analytical methodology that is fit-for-purpose for their individual mRNA-LNP product formulation measurement needs.  The development of innovative and reproducible test methods based on the consensus recommendations presented in the guide are currently under discussion with stakeholders.  For more information, please visit: https://www.astm.org/workitem-wk756

Orthogonal and complementary analytical methods for characterizing nano-enabled medical products

Orthogonal and/or complementary analytical methods (Figure 2) are essential for characterizing the physicochemical and biological critical quality attributes of nano-enabled medical products (both therapeutics and medical devices).  The current definitions and application of orthogonal and complementary measurements by both drug product manufacturers and regulatory authorities can sometimes be a source of confusion and controversy.  To bring greater clarity to the understanding and application of orthogonal and complementary in the context of nanoparticle methods and measurements, a consortium of international measurement laboratories has been formed.  This consortium was established to discuss and facilitate the development of a consensus perspective regarding orthogonal and complementary terminology.  The team has recently developed and published an opinion paper on the definition and application of orthogonal and complementary measurements relevant to particle size and particle size distribution of nanomaterials in drug products.  Future efforts for clarifying the definitions of terminology relevant to nano-enabled medical products will focus on important measurements related to in vitro toxicity, in vitro viability, in vivo potency, etc.  In addition, efforts are now focused on developing a comprehensive terminology standard for orthogonal and complementary particle size measurements for nano-enabled medical products in ISO TC229.  

• For additional information on future terminology projects relevant to nano-enabled medical products, please see: Orthogonal Measurements
   

  

Awards and Honors

NIST Outstanding Mentor Award (2017)
Sigma Xi Distinguished Lecturer (2015 to 2017)
Sigma Xi Member (2005 to present)

Professional Committees and Service

Chair-Elect of the ACS – Analytical Chemistry Division, (2023 to present)
American Chemical Society (ACS) Councilor – Analytical Chemistry Division (2019 to present)
ACS Project SEED Awards Committee Co-Chair
Member – Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Nano Working Group (since 2018)
ASTM International E56.08 Chair – Nano-Enabled Medical Products (2017 to present)
Member – American Chemical Society (1998 to present)
Advisor – Biomedical Science Careers Program – Harvard Medical School (1996 to present)